Scholarlink

<p>Lupus nephritis (LN) is a&#xa0;form of glomerulonephritis that is considered a&#xa0;particularly severe organ manifestation, occurring in 20–60% of patients with systemic lupus erythematosus (SLE) and substantially contributing to lupus-related morbidity and mortality. Accordingly, if renal involvement is suspected, a&#xa0;kidney biopsy should be indicated at a&#xa0;low threshold to confirm the diagnosis. The histological assessment of LN according to the different histopathological classes and the estimation of the inflammatory activity and chronicity index are decisive for the choice of the treatment regimen. There have been no innovations in this area for many years but there are now increasingly more new treatment options, especially in the treatment of LN classes&#xa0;III and&#xa0;IV with or without existing class&#xa0;V. These include belimumab, voclosporin and obinutuzumab that can be used in addition to the standard of care. Other promising substances are also currently being investigated in phase 2 and&#xa0;3 studies. New data also enable a&#xa0;better definition of the treatment goal. It has been shown that an early response and a stable clinical remission of at least 3&#xa0;years lead to a&#xa0;reduction in significant renal end-organ damage. Accordingly, it can be concluded that a stable maintenance therapy for avoidance of disease exacerbations should, if necessary, be continued for a&#xa0;longer period of time before a&#xa0;slow reduction in immunosuppressive therapy is initiated.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Update Lupusnephritis

  • 期刊论文

  • 发表日期：

    2025年12月17日

查看全文
  • Simone Cosima Boedecker-Lips,
  • Julia Weinmann-Menke

摘要

Lupus nephritis (LN) is a form of glomerulonephritis that is considered a particularly severe organ manifestation, occurring in 20–60% of patients with systemic lupus erythematosus (SLE) and substantially contributing to lupus-related morbidity and mortality. Accordingly, if renal involvement is suspected, a kidney biopsy should be indicated at a low threshold to confirm the diagnosis. The histological assessment of LN according to the different histopathological classes and the estimation of the inflammatory activity and chronicity index are decisive for the choice of the treatment regimen. There have been no innovations in this area for many years but there are now increasingly more new treatment options, especially in the treatment of LN classes III and IV with or without existing class V. These include belimumab, voclosporin and obinutuzumab that can be used in addition to the standard of care. Other promising substances are also currently being investigated in phase 2 and 3 studies. New data also enable a better definition of the treatment goal. It has been shown that an early response and a stable clinical remission of at least 3 years lead to a reduction in significant renal end-organ damage. Accordingly, it can be concluded that a stable maintenance therapy for avoidance of disease exacerbations should, if necessary, be continued for a longer period of time before a slow reduction in immunosuppressive therapy is initiated.